Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

BHVN

Biohaven Ltd

Jan 16 • 04:00PM ET

13.14

+1.22 10.23 %

Healthcare • Biotechnology • USA • NYSE

Peers: VRTX AMGN REGN GILD BMRN NBIX ALNY INCY SRPT EXEL

| Held by: XBI IWM VXF PINK IBB IWO SCHA VTWO VHT FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-7.60	Insider Own	13.01%	Shs Outstand	145.19M	Perf Week	18.27%
Market Cap	1.91B	Forward P/E	-	EPS next Y	-3.07	Insider Trans	30.52%	Shs Float	126.30M	Perf Month	19.13%
Enterprise Value	1.96B	PEG	-	EPS next Q	-1.18	Inst Own	59.81%	Short Float	15.83%	Perf Quarter	-20.27%
Income	-780.11M	P/S	-	EPS this Y	29.27%	Inst Trans	-1.62%	Short Ratio	4.85	Perf Half Y	-6.48%
Sales	0.00M	P/B	-	EPS next Y	53.16%	ROA	-169.65%	Short Interest	19.99M	Perf YTD	16.39%
Book/sh	-0.16	P/C	7.32	EPS next 5Y	38.57%	ROE	-522.08%	52W High	44.28 -70.33%	Perf Year	-63.69%
Cash/sh	1.80	P/FCF	-	EPS past 3/5Y	-40.84% -49.78%	ROIC	-267.62%	52W Low	7.48 75.67%	Perf 3Y	-22.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.57% 10.37%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.76%	Oper. Margin	-	ATR (14)	1.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.86	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.80	Recom	1.81
Dividend Gr. 3/5Y	- -	Current Ratio	2.86	EPS Q/Q	3.50%	SMA20	17.28%	Beta	3.54	Target Price	19.93
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	29.04%	Rel Volume	1.00	Prev Close	11.92
Employees	256	LT Debt/Eq	-	Earnings	Nov 10 BMO	SMA200	-10.34%	Avg Volume	4.12M	Price	13.14
IPO	May 04, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.73% -100.00%	Trades		Volume	4,113,906	Change	10.23%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Downgrade	H.C. Wainwright	Buy → Neutral	$11
Nov-26-25	Downgrade	UBS	Buy → Neutral	$11
Nov-06-25	Downgrade	Bernstein	Outperform → Mkt Perform	$9
Nov-05-25	Downgrade	BofA Securities	Buy → Neutral	$10
Sep-17-25	Initiated	Citigroup	Buy	$28
Sep-03-25	Initiated	Raymond James	Strong Buy	$75
May-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$21
Feb-11-25	Initiated	Deutsche Bank	Buy	$65
Sep-16-24	Initiated	Jefferies	Buy	$57
Sep-04-24	Initiated	Bernstein	Outperform	$55
Jul-24-24	Initiated	Morgan Stanley	Overweight	$58
Feb-16-24	Initiated	RBC Capital Mkts	Outperform	$62
Feb-06-24	Initiated	UBS	Buy	$59
Dec-22-23	Initiated	H.C. Wainwright	Buy	$50
Dec-08-23	Initiated	Robert W. Baird	Outperform	$58
Jan-24-23	Initiated	SVB Securities	Outperform	$24
Jan-04-23	Initiated	JP Morgan	Overweight	$23
Dec-02-22	Initiated	BTIG Research	Buy	$24
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$158 → $27
Oct-12-22	Initiated	Piper Sandler	Overweight	$23

Show Previous Ratings

Jan-14-26 09:48PM	Biohaven (BHVN) Stock Is Trending Overnight - Here's What You Should Know (Benzinga) +6.65%
Jan-12-26 11:15AM	Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +6.57%
Jan-07-26 07:00AM	Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 (PR Newswire) +22.04%
Dec-26-25 02:56PM	Christmas Week Brings S&P 500 Records, Tech Volatility (Schaeffer's Research)
02:14PM	These Stocks Are Moving the Most Today: Nvidia, Apple, Tesla, Coupang, Micron, Lam Research, Newmont, Moderna, and More (Barrons.com)
10:25AM	Loading…
10:25AM	Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial (Schaeffer's Research)
08:18AM	Biohaven sinks on disappointing trial and other early movers (MarketWatch)
07:39AM	These Stocks Are Moving the Most Today: Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More (Barrons.com)
06:07AM	S&P Futures Muted in Thin Post-Christmas Trade (Barchart)
04:27AM	Stock Market Today: Dow, S&P 500 set to hover near fresh records in thin holiday trading; silver, gold and copper rally continue, industrial metals also climb (MarketWatch)
Dec-24-25 01:00PM	Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder (PR Newswire)
09:55AM	Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know (Zacks)
Dec-19-25 12:00PM	Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-11-25 07:00AM	Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress (PR Newswire) +7.92%
Dec-04-25 09:55AM	How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52% (Zacks) +5.37%
09:15AM	Loading…
Dec-03-25 09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly)
Nov-24-25 08:40AM	Jim Cramer on Biohaven: "The Stock Seems Very Low to Me" (Insider Monkey)
Nov-20-25 12:37PM	Biohaven Insiders Bet $33 Million on a Turnaround (MarketBeat)
Nov-18-25 09:45AM	Carl Icahn Makes Another Huge Insider Purchase (24/7 Wall St.) +14.27%
Nov-16-25 10:13PM	William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth (Insider Monkey)
Nov-13-25 04:05PM	Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M (PR Newswire)
Nov-12-25 07:15AM	Biohaven Announces Pricing of $175 Million Public Offering of Common Shares (PR Newswire) -6.69%
Nov-11-25 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire) +9.37%
Nov-10-25 06:58AM	Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -5.69%
Nov-05-25 04:28PM	Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug (Investor's Business Daily) -40.22%
06:59AM	Knocked back by the FDA, Biohaven turns to major cost cuts (BioPharma Dive)
Nov-04-25 08:06PM	FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia (PR Newswire) -6.06%
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly) +8.97%
Sep-14-25 05:30AM	Biotech stocks: Who wins and who loses if RFK, Jr. goes (Investing.com)
04:14PM	Loading…
Sep-09-25 04:14PM	Shareholders of Biohaven Ltd. (BHVN): Protect Your Rights Before September 12, 2025 - Contact Levi & Korsinsky (Newsfile)
Sep-03-25 05:48PM	Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN (Business Wire)
12:01PM	Biohavens rare disease drug is ready to ship on Day 1 following FDA approval (BioPharma Dive)
Aug-22-25 06:18PM	Why Biohaven Stock Zoomed More Than 6% Higher Today (Motley Fool) +6.34%
04:15PM	Biohaven Surges After FDA Cancels Key Meeting. But Is It Good News? (Investor's Business Daily)
09:14AM	Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting (Benzinga)
06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
Aug-18-25 04:55PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 12, 2025 - Biohaven Ltd. (BHVN) (Newsfile)
Aug-17-25 11:41PM	Leerink Lowers Biohaven (BHVN) PT to $50 Following Q2 Report, Acknowledging Positive Pipeline Progress (Insider Monkey)
Aug-11-25 07:00AM	Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -9.02%
Aug-08-25 04:23PM	Biohaven Ltd. (BHVN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 12, 2025 (Newsfile)
Jul-29-25 08:45AM	Shareholders of Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN (PR Newswire)
Jul-21-25 04:37PM	Did You Lose Money on Biohaven Ltd. (BHVN)? Levi & Korsinsky Urges Investors to Act Before September 12, 2025 (Newsfile)
Jul-15-25 08:59AM	Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform (Insider Monkey) -6.55%
Jun-10-25 02:00PM	Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development (GlobeNewswire)
May-29-25 07:01AM	Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor (PR Newswire)
12:16AM	Biohaven Ltd. (BHVN)'s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy (Insider Monkey)
May-28-25 03:00PM	Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN) (PR Newswire)
07:30AM	Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors (PR Newswire)
May-15-25 06:03PM	Why Biohaven Stock Dove by Nearly 20% on Thursday (Motley Fool) -19.53%
02:06PM	Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug (Investor's Business Daily)
01:22PM	Why Is Biohaven Stock Falling On Thursday? (Benzinga)
May-14-25 06:43PM	FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia (PR Newswire)
May-12-25 04:05PM	Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -5.11%
May-09-25 08:49AM	Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts (Insider Monkey)
May-05-25 08:00AM	Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (Seeking Alpha)
Apr-28-25 01:16PM	Why BioHaven Stock Is Soaring Today (Motley Fool) +9.58%
07:30AM	Biohaven Announces Investment up to $600 Million by Oberland Capital (PR Newswire)
Apr-26-25 12:10PM	Biohaven share price undervaluing pipeline potential, says RBC Capital (TipRanks)
Apr-25-25 05:10PM	Why Biohaven Stock Plummeted by More Than 15% Today (Motley Fool) -15.21% +9.58%
Apr-23-25 06:12PM	Jim Cramer Says Biohaven (BHVN) Is "Too Cheap" and He's a Buyer at $21 (Insider Monkey) +9.24%
01:02PM	Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-18-25 03:36AM	Xenon- A Later Stage Story (Seeking Alpha)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha) +9.05%
Apr-05-25 09:00AM	Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
Apr-03-25 09:30AM	Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March (Motley Fool) -13.22%
Apr-01-25 11:55AM	American Century Companies boosts stake in Biohaven, ETF Daily News says (TipRanks) -5.99%
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-09-25 04:37PM	Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 (Insider Monkey)
Mar-07-25 10:31AM	Biohaven price target lowered to $63 from $69 at Morgan Stanley (TipRanks)
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Mar-03-25 07:31AM	Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 (PR Newswire) -13.77%
07:30AM	Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-11-25 06:42PM	Why Biohaven Stock Triumphed on Tuesday (Motley Fool) +11.19%
04:11PM	Biohaven Just Hurdled An FDA Setback And Its Moving Lines (Investor's Business Daily)
01:29PM	Why Biohaven (BHVN) Stock Is Rallying Today (Insider Monkey)
07:30AM	Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia (PR Newswire)
Jan-24-25 05:48PM	Pfizer to Pay $60 Million in Kickback, False Claims Settlement (The Wall Street Journal)
Jan-13-25 11:15AM	Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy (PR Newswire)
Jan-12-25 08:04PM	Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs (GlobeNewswire)
Jan-07-25 05:54PM	Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-17-24 02:23PM	Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval (Benzinga) -5.60%
06:06AM	Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-16-24 07:30AM	Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates (PR Newswire) +7.72%
Dec-06-24 07:30AM	Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting (PR Newswire)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga)
07:30AM	Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity (PR Newswire)
Nov-12-24 04:05PM	Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +10.75%
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
Oct-02-24 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Oct-01-24 06:00AM	Biohaven Announces Pricing of $250 Million Public Offering of Common Shares (PR Newswire)
Sep-30-24 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire)
07:30AM	Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine (PR Newswire)
Sep-23-24 07:30AM	Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) (PR Newswire) +13.74%
Sep-20-24 07:09PM	Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia (PR Newswire)
Aug-08-24 08:21PM	Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? (Insider Monkey) +5.93% +6.25%
04:05PM	Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
Jul-01-24 07:00AM	Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors (GlobeNewswire)

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gentile Kimberly	SVP, Clinical Operations	Jan 05 '26	Option Exercise	0.00	3,750	0	101,513	Jan 07 09:34 PM
Buten Matthew	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	4,250	0	198,246	Jan 07 09:33 PM
Coric Vlad	Chief Executive Officer	Jan 05 '26	Option Exercise	0.00	14,250	0	1,811,398	Jan 07 09:32 PM
Car Bruce	Chief Scientific Officer	Jan 05 '26	Option Exercise	0.00	4,750	0	10,096	Jan 07 09:32 PM
Clark George C.	VP, Chief Accounting Officer	Jan 05 '26	Option Exercise	0.00	2,500	0	68,095	Jan 07 09:31 PM
Clark George C.	VP, Chief Accounting Officer	Nov 17 '25	Buy	8.52	17,000	144,770	20,000	Nov 18 07:29 AM
Bailey Gregory	Director	Nov 13 '25	Buy	7.50	400,000	3,000,000	2,020,071	Nov 17 07:31 AM
CHILDS JOHN W	Director	Nov 13 '25	Buy	7.50	3,333,333	24,999,998	5,653,904	Nov 17 07:30 AM
Coric Vlad	Chief Executive Officer	Nov 13 '25	Buy	7.50	666,666	4,999,995	1,195,275	Nov 17 07:30 AM
CHILDS JOHN W	Director	Mar 04 '25	Buy	30.47	32,700	996,238	2,320,571	Mar 05 07:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BHVN

Biohaven Ltd

Upgrade your FINVIZ experience